Physician Case Conferences

Home > Blog > Physician Case Conferences

Tag: Physician Case Conferences

By

Dellenbaugh, Timothy, MD

Dr. Dellenbaugh attended medical school at the University of Illinois, and completed his residency in psychiatry at Kansas University School of Medicine. After residency he worked in community mental health before joining Western Missouri Mental Health and the faculty at University of Missouri-Kansas City. He is Associate Professor of Psychiatry and Associate Dean representing Center for Behavior Medicine to the School of Medicine and Assistant Medical Director for CBM. He is on the American Board of Psychiatry and Neurology Pilot MOC committee and previously was on the exam writing and assembly committee for general psychiatry. He has chaired a committee on psychiatric pharmacogenomics for the Missouri Department of Mental Health. He has collaborated with faculty from the UMKC-School of Pharmacy on more than 15 clinical trials in the area of schizophrenia and has given more than 24 invited lectures on topics related to schizophrenia, memory, learning, pharmacogenomics, and psychiatric genetics at local, regional and national meetings.

Presentation(s): 

Psychiatric Genetics 101


 

 

By

Burgess, Doug, MD

Doug Burgess is an addiction psychiatrist who joined Truman Medical Centers in 2011. He received his residency training at Duke University where he served as chief resident during his final year. He completed a fellowship in addiction psychiatry at the Medical University of South Carolina in Charleston. He was the medical director of outpatient psychiatric services until February of 2019 when he transitioned to the role of Medical Director of Addiction Services. Clinically, he sees patients in TMC’s substance use disorder specialty clinic which provides evidence based care to over 800 patients. He is also a treating clinician for the NFL’s Program for Substances of Abuse. Locally, Doug leads regional trainings related to mental health and substance use disorders. He is on the steering committee for the region’s EPICC program, facilitates Missouri’s Opioid Use Disorder ECHO group and actively participates in the area’s perinatal collaborative. He has received Missouri’s Department of Mental Health Addiction Medical Champion Award and was recognized as one of Kansas City’s “Top Docs” by Ingram’s Magazine in 2019.

Presentation(s): 

1. Opioid Use Disorder ECHO

2. Chronic Disease Model of Addiction: Implications for treatment of Opioid Use Disorders and Measuring Success 

 

 

By

Enochs, Will, MD

William Enochs, MD, graduated from Truman State University in 2001 with a Bachelor of Science in Business Administration. He then completed his prerequisite course work for Medical School from the University of Missouri Kansas City in 2011 and went on to complete his Doctorate of Medicine from UMKC in 2015. Dr. Enochs was a firefighter/EMT-B with the Claycomo Fire Department from 2008-2015. From 2015-2019 he was a Psychiatry Resident with the MO Department of Mental Health and UMKC. His research experience includes REM sleep and pain correlation, Corprophagia/Kluver-Bucey case report, transfer of care and efficacy of Buprenorphine for treatment of pain in individuals with chronic pain and opioid dependence. Dr. Enochs is currently the OD Psychiatrist at Northwest Missouri Psychiatric Rehabilitation Center, a Psychiatric Resident Physician at TMC/CBM, an education instructor with Youngblood Skills Lab, and is also an instructor for the KCPD Crisis Intervention Team (CIT).

Presentation(s): 

Mass Shootings: Problems and Perspective

By

Psychogenic Polydipsia

Speaker(s):

Fei Cao, MD, PhD

Presentation:

This case report was from a patient who was a long-term resident from the Center of Behavioral Medicine (CBM) with the primary diagnosis of Schizophrenia, alcohol use disorder, Stimulant use disorder (methamphetamine), Hallucinogen use disorder (LSD), and Cannabis use disorder. He stayed in the CBM for years without remarkable physical complaint initially. One day he went to Gastroenterology (GI) clinic with CBM staff for routine work-up after treating his asymptomatic hepatitis C, and he told the gastroenterologist that he was craving for water with epigastric pain. Further work-up revealed he had mild bilateral hydroureteronephrosis through abdominal CT and chronic hyponatremia through repeated comprehensive chemical panel (CMP). Further monitoring indicated he had approximately 15 L urine output every day. Then he was diagnosed with Psychogenic polydipsia by multiple-discipline team using deprivation test with and without desmopressin. This presentation’s goals are to introduce clinical features of Psychogenic polydipsia, its gold diagnostic test and differential diagnosis, and its management plan (especially for patients with chronic and/or severe mental illness). 

Objectives:

  1. Introduce clinical features of Psychogenic polydipsia.
  2. Understand the diagnostic criteria for Psychogenic polydipsia and its related differential diagnosis.
  3. Understand the comprehensive approaches to manage Psychogenic polydipsia

 

By

Cao, Fei, MD, PhD

Dr. Fei Cao finished his MD and Ph. D combined program in Tongji Medical school, Huazhong University of Science and Technology, one of the top medical schools in China. His clinical and research interests initially focused on interventional pain management. In 2009, Fei went to MD. Anderson Cancer Center at Houston, Texas, to seek his postdoctoral training of comprehensive management for advanced cancer pain. In 2010, he moved to the Department of Neuroscience, Baylor College of Medicine, and continued his research in pain and other neurodegenerative diseases. Under the supervision of some top neuroscientists in the USA, Fei gradually realized integrated approaches with further understanding underlying neurological and psychiatric mechanisms would be the only solution for chronic pain management in the long run. Then Fei switched his clinical interests to clinical neuroscience (Psychiatry).

Currently Fei is a second-year resident working at Department of Psychiatry, the University of Missouri in Kansas City. He is planning to apply for pain fellowship after his residency training and his career goal is to help patients with chronic pain through an integrated neuropsychiatric way. 

Presentation(s): 

Psychogenic Non-Epileptic Seizures

Psychogenic Polydipsia

By

Psychogenic Non-Epileptic Seizures

Speaker(s):

Fei Cao, MD, PhD

Presentation: This case report was from a patient who was seen by neurologists at Truman medical Center with seemingly intractable seizure activities on the maximal dosing of multiple anti-seizure medication trials. After long-term follow up and multiple-time EEG testing, patient was finally diagnosed with Psychological non-epileptic seizure (PNES), also known as pseudo-seizure in the layman’s term. The presentation’s goals are to introduce some background knowledge about PNES, highlight the difference between PNES and epilepsy, and upgrade the new diagnostic criteria of PNES from DSM-V and novel management approaches. The presentation aims to reach a wide audience of practitioners in the field and helps them further understand PNES, which may be severely underestimated and unrecognized among patients with mental illness.

Objectives:

  1. Introduce clinical features of PNES
  2. Understand the DSM-5 criteria for PNES and related Conversion Disorder
  3. Upgrade new approaches to manage PNES

 

By

Kattula, Ambika, MD

Kattula is a second-year resident psychiatrist at University of Missouri Kansas City, in Kansas City, Missouri. Kattula completed a medical degree from Andhra Medical College in India. After practicing medicine in India, she moved to USA with her family. She worked as a clinical observer at various hospitals in Iowa including University of Iowa, Trinity Health Care and Mercy Care, and also at St. Mary’s hospital in Connecticut. Along with familiarizing the US clinical system, she pursued an interest in research at University of Iowa in the area of prostate cancer research in the lab of Dr. David Lubaroff. Later, due to her interest in psychiatry, she joined Dr. John Wemmie’s lab in the Department of Psychiatry at the University of Iowa where her focus was the utilization of proton exchange MRI to study metabolic abnormalities in the brain. Kattula’s research works were culminated in poster presentations and publications.

During Kattula’s residency at UMKC, she has been receiving rigorous training in managing patients of ages ranging from 18 to 60 with wide variety of psychological disorders of varying severity. During her first year, she presented a poster on the topic of “managing psychiatric/behavioral problems in a patient with chromosome 18 deletion syndrome” in American Psychiatry Association Meeting-2018, New York City, NY along with coauthoring 2 other posters. Recently, her abstract regarding Cognitive Enhancement Therapy in real-world schizophrenia population got accepted for American Psychiatry Association meeting that will be held in May, 2019.

Presentation(s): 

Substance-Induced Neurocognitive Disorder

By

Substance-Induced Neurocognitive Disorder

Speaker(s):

Ambika Kattula, MD

Presentation: Ms. T is a 27-year-old Caucasian female with a past medical history of bipolar disorder with psychotic features, methamphetamine use disorder and cannabis use disorder admitted to our forensic inpatient unit after she was found incompetent to stand trial on charges of burglary and stealing related offense. She was misusing multiple substances including methamphetamine, marijuana, inhalants, opioids and benzodiazepines on daily basis for several years starting at the age of 18 until incarceration a few months before the current admission. Her main presenting symptoms including mood symptoms and anxiety were well controlled during first month of hospitalization with medication regimen of oral valproic acid 1000mg at bed time for mood stabilization and oral paliperidone 6mg daily for psychosis. However, cognitive deficits of memory and attention became apparent gradually. Psychology testing demonstrated impairment in multiple cognitive domains. Medical diagnoses as cause of cognitive impairment were excluded with the help of laboratory testing and MRI brain. She was finally given diagnosis of Substance/Medication-Induced Major Neurocognitive Disorder. This presentation gives an overview of this case followed by discussion of diagnostic criteria and risk factors of substance induced neurocognitive disorder with a brief view of cognitive deficits due to few specific substances, consequences of cognitive impairment and lastly, therapeutic strategies.

Objectives:

  1. Review DSM 5 criteria for Substance/Medication-Induced Major Neurocognitive Disorder
  2. Identify risk factors for Substance/Medication-Induced Major Neurocognitive Disorder
  3. Describe cognitive deficits caused by few commonly misused substances
  4. Identify feasible therapeutic strategies that can be acquired to help patients

Kattula_PPDownload